Craig-Hallum Maintains Buy on Xtant Medical Hldgs, Raises Price Target to $1.2
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a 'Buy' rating on Xtant Medical Hldgs (AMEX:XTNT) and raises the price target from $1 to $1.2.
July 11, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum analyst maintains a 'Buy' rating on Xtant Medical Hldgs and raises the price target from $1 to $1.2.
The 'Buy' rating maintained by Craig-Hallum analyst and the increase in price target from $1 to $1.2 indicates a positive outlook for Xtant Medical Hldgs. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100